Charles M. Manyelo

Charles M. Manyelo

Auto-generated profile, based on publicly available information

Charles M. Manyelo

Stellenbosch University, South Africa

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
CMCharles M. Manyelo
Charles M. Manyelo
RSRegan S. Solomons
Regan S. Solomons
GWGerhard Walzl
Gerhard Walzl
NCNovel N Chegou
Novel N Chegou
Tuberculous meningitis (TBM) is the most devastating form of tuberculosis (TB), causing high mortality or disability. Clinical management of the disease is challenging due to limitations of the existing diagnostic approaches. Our knowledge on the immunology and pathogenesis of the disease is currently limited. More research is urgently needed to enhance our understanding of the immunopathogenesis of the disease and guide us toward the identification of targets that may be useful for vaccines or host-directed therapeutics.

16 April 2019 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
CMCharles M. Manyelo
Charles M. Manyelo
RSRegan Hi Solomons
Regan Hi Solomons
CSCandice I. Snyders
Candice I. Snyders
PMPortia M. Manngo
Portia M. Manngo
HMHygon Mutavhatsindi
Hygon Mutavhatsindi
NCNovel N Chegou
Novel N Chegou
Background. The diagnosis of tuberculous meningitis (TBM) especially in children is challenging. New tests are urgently needed for the diagnosis of the disease, especially in resource-limited settings.Methods. We collected cerebrospinal fluid (CSF) samples from children presenting with symptoms requiring investigation for meningitis at a tertiary hospital in Cape Town, South Africa. Children were later classified as TBM or no TBM using published case definitions. Using a multiplex platform, we investigated the concentrations of biomarkers comprising a previously established 3-marker biosignature (VEGF, IL-13, and LL-37) and other potentially useful host biomarkers as diagnostic candidates for TBM.Findings. Out of 47 children, age, 3 months to 13 years, 23 were diagnosed with TBM and six (16%) were HIV-infected. We validated the previously identified CSF biosignature (sensitivity of 95.7% (95% CI, 79.0-99.2%) and specificity of 37.5% (95% CI, 21.2-57.3%)). However, substitution of IL-13 and LL-37 with IFN-γand MPO, respectively, resulted in improved accuracy (area under the ROC curveAUC=0.97, 95% CI, 0.92-1.00, up to 91.3% (21/23) sensitivity and up to 100% (24/24) specificity). An alternative four-marker biosignature (sICAM-1, MPO, CXCL8, and IFN-γ) also showed potential, with an AUC of 0.97.Conclusion. We validated a previously identified CSF biosignature and showed that refinement of this biosignature by incorporation of other biomarkers diagnosed TBM with high accuracy. Incorporation of these biomarkers into a point-of-care or bedside diagnostic test platform may result in the improved management of TBM in children.

30 April 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMCharles M. Manyelo
Charles M. Manyelo
NCNovel N Chegou
Novel N Chegou
JSJames Seddon
James Seddon
CSCandice I. Snyders
Candice I. Snyders
HMHygon Mutavhatsindi
Hygon Mutavhatsindi
RSRegan Hi Solomons
Regan Hi Solomons
Introduction: Stroke is a common complication in children with tuberculous meningitis (TBM). Host proteins may give us insight into the mechanisms of stroke in TBM and serve as biomarkers for detection of stroke, however, they have not been widely explored. In this study, we compared the concentrations of cerebrospinal fluid (CSF) and serum proteins between children who had TBM-related stroke and children with TBM without stroke. Methods: We collected CSF and serum from 47 children consecutively admitted to the Tygerberg Academic Hospital in Cape Town, South Africa between November 2016, and November 2017, on suspicion of having TBM. A multiplex platform was used to measure the concentrations of 69 host proteins in CSF and serum from all study participants. Results: After classification of study participants, 23 (48.9%) out of the 47 study participants were diagnosed with TBM, of which 14 (60.9%) demonstrated radiological arterial ischemic infarction. The levels of lipocalin-2, sRAGE, IP-10/ CXCL10, sVCAM-1, MMP-1, and PDGF-AA in CSF samples and the levels of D-dimer, ADAMTS13, SAA, ferritin, MCP-1/ CCL2, GDF-15 and IL-13 in serum samples were statistically different between children who had TBM-related stroke and children with TBM without stroke. After correcting for multiple testing, only the levels of sVCAM-1, MMP-1, sRAGE, and IP-10/ CXCL10 in CSF were statistically different between the two groups. CSF and serum protein biosignatures indicated stroke in children diagnosed with TBM with up to 100% sensitivity and 88.9% specificity. Conclusion: Serum and CSF proteins may serve as biomarkers for identifying individuals with stroke amongst children diagnosed with TBM at admission and may guide us to understand the biology of stroke in TBM. This was a pilot study, and thus further investigations in larger studies are needed.

13 June 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
CMCharles M Manyelo
Charles M Manyelo
RSRegan Hi Solomons
Regan Hi Solomons
CSCandice Irene Snyders
Candice Irene Snyders
KSKim Stanley
Kim Stanley
GWGerhard Walzl
Gerhard Walzl
NCNovel N Chegou
Novel N Chegou
Background: Tuberculous meningitis (TBM) is the most severe form of tuberculosis and results in high morbidity and mortality in children. Diagnostic delay contributes to the poor outcome. There is an urgent need for new tools for the rapid diagnosis of TBM, especially in children. Methods: We collected serum samples from children in whom TBM was suspected at a tertiary hospital in Cape Town, South Africa. Children were subsequently classified as having TBM or no TBM using a published uniform research case-definition. Using a multiplex cytokine array platform, we investigated the concentrations of serum biomarkers comprising 7-markers that were previously found to be of value in the diagnosis of adult pulmonary TB (CRP, SAA, CFH, IFN-γ, IP-10, Apo-AI and transthyretin) plus other potentially useful host biomarkers as diagnostic candidates for TBM. Findings: Of 47 children included in the study, 23 (48.9%) had a final diagnosis of TBM of which six had HIV co-infection. A modified version of the adult 7-marker biosignature in which transthyretin was replaced by NCAM1, diagnosed TBM in children with AUC of 0.80 (95% CI, 0.67-0.92), sensitivity of 73.9% (95% CI, 51.6-89.8%) and specificity of 66.7% (95% CI, 44.7-84.4%). A new childhood TBM specific 3-marker biosignature (adipsin, Aβ42 and IL-10) showed potential in the diagnosis of TBM, with AUC of 0.84 (95% CI, 0.73-0.96), sensitivity of 82.6% (95 CI, 61.2-95.0%) and specificity of 75.0% (95% CI, 53.3-90.2%) after leave-one-out cross validation. Conclusion: An adult 7-marker serum protein biosignature showed potential in the diagnosis of TBM in children. However, a smaller childhood TBM-specific biosignature demonstrated improved performance characteristics. Our data indicates that blood-based biomarkers may be useful in the diagnosis of childhood TBM and require further investigation.

29 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
OEOsagie Eribo
Osagie Eribo
EGElsje-Marie Geldenhuys
Elsje-Marie Geldenhuys
MOMumin Ozturk
Mumin Ozturk
NANasiema Allie
Nasiema Allie
MNMargaret B Nolan
Margaret B Nolan
NCNovel N Chegou
Novel N Chegou
Background: Anti-tuberculosis (anti-TB) antibiotics alter the gut microbiome, potentially affecting the host physiology and immune response. Here, we investigated the impact of anti-TB antibiotics on host gut microbiota, immune response, and Mtb control. Methods: We pre-treated mice with isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) for two months, followed by intranasal Mtb infection five days post-HRZE cessation. HRZE pre-treated mice received faecal microbiota transplants (FMT) or phosphate-buffered sa-line (PBS) pre- and post-infection. Faecal DNA was isolated, and 16S rRNA gene se-quencing was performed. Mycobacterial burden, histology, and immune response were assessed in tissues four weeks post-infection. Results: We observed an enrichment of Bacteroides, Alistipes, Alloprevotella, Paraprevotella, and Colidextribacter, and depletion of Clostridia UCG 014, Roseburia, Ruminococcus, and Rikenellaceae RC9 gut group in HRZE pre-treated Mtb-exposed mice compared to infected mice without HRZE (control group). HRZE pre-treatment followed by Mtb infection was associated with marked ileal histo-morphological damage compared to infection alone. Furthermore, gut microbiota alter-ations in HRZE pre-treated mice were associated with poor control of the mycobacterial burden, reduced frequencies of CD4+ T and CD68+ macrophage cell populations, and altered release of IFN-γ, IL-6, and PD-1. Notably, although not completely, FMT improved ileal features, normalised microbiota taxa abundance, lowered Mtb burden, and rescued impaired immune phenotypes. Conclusions: These data highlight the untoward con-sequences of recent anti-TB antibiotics for host control of subsequent Mtb infection and suggest a potential therapeutic avenue for mitigating the effects of HRZE-induced mi-crobiota dysbiosis through FMT or probiotics-associated host-directed therapies to prevent TB recurrence.